Massey’s palliative care clinical director named a visionary in his field
Patrick Coyne, M.S.N., A.P.R.N., F.A.A.N., clinical director of the Palliative Care Program at VCU Massey Cancer Center, has been named one of the 30 most influential leaders in hospice and palliative medicine, the medical specialty focused on relieving suffering and improving quality of life for people with serious illnesses. Coyne was recognized as a visionary by his professional peers for his role in advancing hospice and palliative medicine.
Bacterial cells in the gut found to produce steroid hormones that could have implications for prostate and colon cancer
Recently, a team of VCU researchers, including VCU Massey Cancer Center researchers Gregory Buck, M.S., Ph.D., and Phillip Hylemon, Ph.D., member of Massey’s Cancer Cell Signaling research program, provided additional evidence that the bacteria found living inside the human gut may represent an endocrine organ. For example, the VCU team discovered that specialized gut bacterial cells produce steroid hormones – much like specialized cells in the pancreas produce the endocrine molecule insulin.
VCU Massey researchers receive $18.1 million grant to lead a public health study on tobacco
VCU Massey Cancer Center researchers Thomas Eissenberg, Ph.D., and Robert Balster, Ph.D., have received an $18.1 million federal grant – VCU’s third largest to date – to study so-called modified risk tobacco products and other novel tobacco products, such as electronic cigarettes, and to develop an evaluation tool to help inform United States tobacco regulatory policy.
Making strides against breast cancer
In honor of Breast Cancer Awareness Month, find out the many ways VCU Massey Cancer Center is making strides in the prevention and treatment of breast cancer and ways in which you can celebrate and support these advances. A National Cancer Institute-designated cancer center, VCU Massey is helping to lead and shape the nation’s fight against breast and other cancers.
Prostate cancer screening: the ongoing debate
Since its adoption by the FDA in 1994, the prostate-specific antigen (PSA) test has reduced prostate cancer mortality rates by 39 percent. Despite the lives saved, whether or how the PSA test should be used for screening is at the center of an ongoing debate. Is the PSA test right for you? The answer to this question varies person to person, so I recommend that you talk to your doctor about your individual risk and educate yourself about the pros and cons of testing.